Target intelligence / Profile preview

Very long-chain polyunsaturated fatty acid (VLC-PUFA)

Target
VLC-PUFA
Molecular classification
Lipid, Polyunsaturated fatty acid
01

Overview

Very long-chain polyunsaturated fatty acids (VLC-PUFAs) are a specialized class of lipids with carbon chains exceeding 24 atoms (typically C26-C38) and multiple double bonds, synthesized primarily by the enzyme ELOVL4 (Agbaga et al., 2008, PNAS). These lipids are essential structural components of membranes in high-activity tissues such as the retina, brain, and testes, where they maintain the fluidity and integrity of specialized microdomains like photoreceptor outer segments (Harker et al., 2014, Journal of Lipid Research). Beyond their structural role, VLC-PUFAs serve as precursors to elovanoids, which are potent bioactive signaling molecules that protect cells against oxidative stress and apoptosis (Bhattacharjee et al., 2017, Science Advances). Mutations in the biosynthetic pathway of VLC-PUFAs are linked to severe pathologies, including Stargardt disease 3 (STGD3), spinocerebellar ataxia type 34 (SCA34), and certain forms of ichthyosis (Ozaki et al., 2015, JAMA Ophthalmology). While VLC-PUFAs are not traditional protein targets for drug inhibition, they are the focus of therapeutic strategies aimed at lipid replacement or the use of synthetic elovanoid derivatives to treat neurodegenerative and retinal disorders (Jun et al., 2017, Scientific Reports).

Other names
Ultra-long chain polyunsaturated fatty acidsVLC-PUFAsC26-C38 polyunsaturated fatty acids
02

Mechanism of action

Metabolic precursors for the synthesis of neuroprotective elovanoids and structural components of specialized membrane microdomains.

03

Biological functions

Membrane structural componentPrecursor to elovanoidsVisual perceptionSpermatogenesisSkin barrier formation
04

Disease associations

Stargardt disease 3Age-related macular degenerationSpinocerebellar ataxia type 34IchthyosisMale infertility
05

Safety considerations

Susceptibility to lipid peroxidationOxidative stress
06

Interacting drugs

Docosahexaenoic acid

2 more in the full profile.

07

Biomarkers

Serum VLC-PUFA levelsELOVL4 gene mutationsElovanoid levels

Beyond the preview

Go deeper on Very long-chain polyunsaturated fatty acid (VLC-PUFA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Very long-chain polyunsaturated fatty acid (VLC-PUFA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call